Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
posted on 2021-05-26, 15:19authored byAdis journals on behalf of:, Luís Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, Nikita A. Zolkin, Ivan V. Kuryshev, Alexey N. Petrov, Antonina V. Artemeva, Arina V. Zinkina-Orikhan
Article full
text
The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).